Alpha Teknova, Inc. (TKNO) 株式分析

企業概要

Alpha Teknova, Inc. is an entity engaged in the production of critical reagents necessary for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, serving both domestic and international markets. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, positioning it as a specialized player in pharmaceutical supply chains and biotechnology support. Its operational scale is defined by a market capitalization of $151.65M and an annual revenue of $40.52M, supported by a workforce of 158 employees. These valuation and revenue figures indicate that the company maintains a mid-cap profile, suggesting a specialized niche role rather than broad market dominance, which is characteristic of firms focused on high-margin, specialized manufacturing inputs for the broader drug development ecosystem.

財務健全性

The company reported a revenue of $40.52M over the trailing twelve months, yet it posted a net income of -$17,259,000 and an EBITDA of -$10,134,000, revealing a significant cost structure where operating expenses substantially exceed gross profits. This disparity between positive revenue and negative net income highlights the heavy investment required for R&D and general administration typical in the specialty drug manufacturing sector. The free cash flow stands at -$2,396,250, indicating that current operations are consuming cash reserves rather than generating liquidity, which limits immediate financial flexibility for capital expenditures without external financing. Margins reflect this financial pressure, with a gross margin of 33.2%, an operating margin of -41.2%, and a profit margin of -42.6%, demonstrating that while the core product line retains value, overall profitability is currently negative. Regarding liquidity and leverage, the company holds $21.34M in cash against $28.27M in total debt, resulting in a debt-to-equity ratio of 41.10, which signifies a leveraged balance sheet where liabilities exceed equity holdings. The current ratio of 4.58 suggests strong short-term liquidity, as current assets are more than four times current liabilities, providing a buffer to meet obligations despite the cash burn rate. Furthermore, the return on equity is -22.8% and the return on assets is -9.3%, metrics that indicate management has not yet achieved positive capital efficiency, as the company is generating losses relative to the shareholders' equity and total asset base.

バリュエーション評価

Valuation metrics present a mixed picture, with a P/E Ratio (TTM) listed as N/A due to negative earnings and a forward P/E of -7.26, implying that the market anticipates a path toward profitability but current pricing models rely on non-earnings-based multiples. The price-to-book ratio is 2.20, suggesting the market prices the stock at a premium of roughly 120% over its tangible book value, which could reflect investor confidence in the intangible value of its reagent patents and future product pipelines. Alternative valuation measures such as the price-to-sales ratio of 3.74 and an EV/EBITDA of -15.65 further highlight that traditional earnings multiples are insufficient, requiring reliance on revenue-based or enterprise value frameworks. The stock's price range over the past year spans from a low of $1.91 to a high of $7.48; assuming a current trading context near the upper end of recent volatility, the price sits significantly above the 52-week low but remains below the recent peak. The beta value of 0.33 indicates that the stock exhibits low volatility relative to the broader market, moving with only about one-third of the intensity of the S&P 500, which offers a defensive characteristic for a high-risk biotech sector. These metrics collectively suggest a high-risk, high-potential-reward profile where valuation is driven by growth expectations rather than current cash flows or earnings stability.

Growth & Income

The company demonstrated a revenue growth rate of 7.8% year-over-year, whereas earnings growth is marked as N/A due to the absence of positive net income, implying that top-line expansion is outpacing any potential for bottom-line profitability in the short term. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders but instead retains all earnings to fund its research and development activities. This reinvestment strategy is essential for a firm with negative returns on equity, as distributing cash would exacerbate its already leveraged position and negative cash flow. The overall growth and income profile is characterized by steady revenue expansion in a specialized niche, coupled with a complete lack of current income generation, positioning the asset strictly as a speculative growth vehicle dependent on future commercialization milestones to restore profitability and enable dividend potential in the future.